CD34 Monoclonal Antibody [QBEND-10]
Catalogue Number: IQ77
Catalogue Number: IQ77M
Catalogue Number: IQ77RPE
Catalogue Number: IQ77FITC
Catalogue Number: IQ77BTN
Item in Stock Secure Online Payments
If you have any questions or require further information, please contact us and one of our scientists will be in touch.
A free sample may be available. Please click here to request this.
Datasheet
Primary Description: | Mouse Anti-Human CD34 [QBEND-10] |
Primary Description: | Mouse Anti-Human CD34 [QBEND-10] |
Primary Description: | Mouse Anti-Human CD34 [QBEND-10]: R-Phycoerythrin (RPE) |
Primary Description: | Mouse Anti-Human CD34 [QBEND-10]: Fluorescein (FITC) |
Primary Description: | Mouse Anti-Human CD34 [QBEND-10]- Biotin |
Target Antigen: | CD34 |
Target Antigen: | CD34 |
Target Antigen: | CD34 |
Target Antigen: | CD34 |
Target Antigen: | CD34 |
Catalogue Number: | IQ77 |
Catalogue Number: | IQ77M |
Catalogue Number: | IQ77RPE |
Catalogue Number: | IQ77FITC |
Catalogue Number: | IQ77BTN |
Quantity: | 0.1mg |
Quantity: | 0.05mg |
Quantity: | 0.05mg |
Quantity: | 0.05mg |
Quantity: | 0.05mg |
Concentration: | 1mg/ml |
Concentration: | 1mg/ml |
Concentration: | 1mg/ml |
Concentration: | 1mg/ml |
Concentration: | 1mg/ml |
Clone: | QBEND-10 |
Clone: | QBEND-10 |
Clone: | QBEND-10 |
Clone: | QBEND-10 |
Clone: | QBEND-10 |
Host: | Mouse |
Host: | Mouse |
Host: | Mouse |
Host: | Mouse |
Host: | Mouse |
Isotype: | IgG1 |
Isotype: | IgG1 |
Isotype: | IgG1 |
Isotype: | IgG1 |
Isotype: | IgG1 |
Myeloma/Fusion Partners: | NSO myeloma cell line |
Myeloma/Fusion Partners: | NSO myeloma cell line |
Myeloma/Fusion Partners: | NSO myeloma cell line |
Myeloma/Fusion Partners: | NSO myeloma cell line |
Myeloma/Fusion Partners: | NSO myeloma cell line |
Immunogen: | Human endothelial vesicles |
Immunogen: | Human endothelial vesicles |
Immunogen: | Human endothelial vesicles |
Immunogen: | Human endothelial vesicles |
Immunogen: | Human endothelial vesicles |
Species Reactivity: | Human, Cynomolgus Monkey, Rhesus monkey |
Species Reactivity: | Human, Cynomolgus Monkey, Rhesus monkey |
Species Reactivity: | Human, Cynomolgus Monkey, Rhesus monkey |
Species Reactivity: | Human, Cynomolgus Monkey, Rhesus monkey |
Species Reactivity: | Human, Cynomolgus Monkey, Rhesus monkey |
Purification: | Protein A affinity chromatography |
Purification: | Protein A affinity chromatography |
Purification: | Protein A affinity chromatography |
Purification: | Protein A affinity chromatography |
Purification: | Protein A affinity chromatography |
Format: | Purified tissue culture supernatant in phosphate buffered saline containing 0.02% sodium azide |
Format: | Purified tissue culture supernatant in phosphate buffered saline containing 0.02% sodium azide |
Format: | Purified antibody containing PBS 0.1% sodium azide |
Format: | Purified IgG conjugated to Fluorescein using Innova Biosciences Lightning-Link®, supplied in Phosphate buffered saline (PBS) containing 0.09% sodium azide |
Format: | Purified antibody (from supernatant) containing PBS + 0.09% sodium azide, conjugated to Biotin |
Applications: | Flow Cyt, IHC-Fr, IP, IHC-P, WB |
Applications: | Flow Cyt, IHC-Fr, IP, IHC-P, WB |
Applications: | Flow Cyt, IHC-Fr, IP, IHC-P, WB |
Applications: | Flow Cyt, IHC-Fr, IP, IHC-P, WB |
Dilutions: | Optimal antibody dilution should be determined by titration, however try atFlow Cyt: 1/50. (methanol fixed cells)IHC-P: 1/50 - 1/100. Do not perform antigen retrievalWB: Use at an assay dependent dilution. Predicted molecular weight: 40 kDa |
Dilutions: | Optimal antibody dilution should be determined by titration, however try atFlow Cyt: 1/50. (methanol fixed cells)IHC-P: 1/50 - 1/100. Do not perform antigen retrievalWB: Use at an assay dependent dilution. Predicted molecular weight: 40 kDa |
Dilutions: | Optimal antibody dilution should be determined by titration, however try atFlow Cyt: 1/50. (methanol fixed cells)IHC-P: 1/50 - 1/100. Do not perform antigen retrievalWB: Use at an assay dependent dilution. Predicted molecular weight: 40 kDa |
Dilutions: | Optimal antibody dilution should be determined by titration, however try atFlow Cyt: 1/50. (methanol fixed cells)IHC-P: 1/50 - 1/100. Do not perform antigen retrievalWB: Use at an assay dependent dilution. Predicted molecular weight: 40 kDa |
Also Known As: | CD34 antibody;CD34 antigen antibody;CD34 molecule antibody;CD34_HUMAN antibody;Cluster designation 34 antibody;Hematopoietic progenitor cell antigen CD34 antibody;HPCA1 antibody |
Also Known As: | CD34 antibody;CD34 antigen antibody;CD34 molecule antibody;CD34_HUMAN antibody;Cluster designation 34 antibody;Hematopoietic progenitor cell antigen CD34 antibody;HPCA1 antibody |
Also Known As: | CD34 antibody;CD34 antigen antibody;CD34 molecule antibody;CD34_HUMAN antibody;Cluster designation 34 antibody;Hematopoietic progenitor cell antigen CD34 antibody;HPCA1 antibody |
Also Known As: | CD34 antibody;CD34 antigen antibody;CD34 molecule antibody;CD34_HUMAN antibody;Cluster designation 34 antibody;Hematopoietic progenitor cell antigen CD34 antibody;HPCA1 antibody |
Also Known As: | CD34 antibody;CD34 antigen antibody;CD34 molecule antibody;CD34_HUMAN antibody;Cluster designation 34 antibody;Hematopoietic progenitor cell antigen CD34 antibody;HPCA1 antibody |
Pubmed ID(s): | 32102682, 30643202, 30833656, 30926422, 30820651, 31011231, 31386624, 31839752, 30589415, 30670979, 29719615, 29959804, 29970982, 27685949, 28170170, 28586042, 28540322, 28588682, 28724792, 28806949, 28817576, 28927128, 29340079, 26880204, 27252357, 27535280, 28836831, 26544791, 25923923, 26010009, 26171042, 26730158, 25810463, 24591638, 24704828, 23639003, 24340136, 20824067, 19763724, 18192970, 9679898, 9301680, 2242851 |
Pubmed ID(s): | 32102682, 30643202, 30833656, 30926422, 30820651, 31011231, 31386624, 31839752, 30589415, 30670979, 29719615, 29959804, 29970982, 27685949, 28170170, 28586042, 28540322, 28588682, 28724792, 28806949, 28817576, 28927128, 29340079, 26880204, 27252357, 27535280, 28836831, 26544791, 25923923, 26010009, 26171042, 26730158, 25810463, 24591638, 24704828, 23639003, 24340136, 20824067, 19763724, 18192970, 9679898, 9301680, 2242851 |
Pubmed ID(s): | 32102682, 30643202, 30833656, 30926422, 30820651, 31011231, 31386624, 31839752, 30589415, 30670979, 29719615, 29959804, 29970982, 27685949, 28170170, 28586042, 28540322, 28588682, 28724792, 28806949, 28817576, 28927128, 29340079, 26880204, 27252357, 27535280, 28836831, 26544791, 25923923, 26010009, 26171042, 26730158, 25810463, 24591638, 24704828, 23639003, 24340136, 20824067, 19763724, 18192970, 9679898, 9301680, 2242851 |
Pubmed ID(s): | 32102682, 30643202, 30833656, 30926422, 30820651, 31011231, 31386624, 31839752, 30589415, 30670979, 29719615, 29959804, 29970982, 27685949, 28170170, 28586042, 28540322, 28588682, 28724792, 28806949, 28817576, 28927128, 29340079, 26880204, 27252357, 27535280, 28836831, 26544791, 25923923, 26010009, 26171042, 26730158, 25810463, 24591638, 24704828, 23639003, 24340136, 20824067, 19763724, 18192970, 9679898, 9301680, 2242851 |
Pubmed ID(s): | 32102682, 30643202, 30833656, 30926422, 30820651, 31011231, 31386624, 31839752, 30589415, 30670979, 29719615, 29959804, 29970982, 27685949, 28170170, 28586042, 28540322, 28588682, 28724792, 28806949, 28817576, 28927128, 29340079, 26880204, 27252357, 27535280, 28836831, 26544791, 25923923, 26010009, 26171042, 26730158, 25810463, 24591638, 24704828, 23639003, 24340136, 20824067, 19763724, 18192970, 9679898, 9301680, 2242851 |
Entrez Gene ID(s): | 101866926, 947, 713858 |
Entrez Gene ID(s): | 101866926, 947, 713858 |
Entrez Gene ID(s): | 101866926, 947, 713858 |
Entrez Gene ID(s): | 101866926, 947, 713858 |
Entrez Gene ID(s): | 101866926, 947, 713858 |
SwissProt ID(s): | p28906 |
SwissProt ID(s): | p28906 |
SwissProt ID(s): | p28906 |
SwissProt ID(s): | p28906 |
SwissProt ID(s): | p28906 |
Omim ID(s): | 142230 |
Omim ID(s): | 142230 |
Omim ID(s): | 142230 |
Omim ID(s): | 142230 |
Omim ID(s): | 142230 |
Citations
Citation Count: | 48 |
Citations: | Liang Y et al. Exosomal microRNA-144 from bone marrow-derived mesenchymal stem cells inhibits the progression of non-small cell lung cancer by targeting CCNE1 and CCNE2. Stem Cell Res Ther 11:87 (2020). Venhuizen JH et al. Differential expression of p120-catenin 1 and 3 isoforms in epithelial tissues. Sci Rep 9:90 (2019). Kim HS et al. Morphological characteristics of vasculogenic mimicry and its correlation with EphA2 expression in gastric adenocarcinoma. Sci Rep 9:3414 (2019). Lu M et al. Enhanced wound healing promotion by immune response-free monkey autologous iPSCs and exosomes vs. their allogeneic counterparts. EBioMedicine 42:443-457 (2019). Grahn A et al. Volumetric imaging: a potential tool to stage upper tract urothelial carcinoma. World J Urol N/A:N/A (2019). Reijnen C et al. Poor outcome in hypoxic endometrial carcinoma is related to vascular density. Br J Cancer 120:1037-1044 (2019). Yu L et al. Exosomes derived from microRNA-199a-overexpressing mesenchymal stem cells inhibit glioma progression by down-regulating AGAP2. Aging (Albany NY) 11:5300-5318 (2019). Jiang X et al. Inhibition of Triple-Negative Breast Cancer Tumor Growth by Electroacupuncture with Encircled Needling and Its Mechanisms in a Mice Xenograft Model. Int J Med Sci 16:1642-1651 (2019). Sidney LE & Hopkinson A Corneal keratocyte transition to mesenchymal stem cell phenotype and reversal using serum-free medium supplemented with fibroblast growth factor-2, transforming growth factor-ß3 and retinoic acid. J Tissue Eng Regen Med 12:e203-e215 (2018). Zhang T et al. HMG-CoA Reductase Inhibitors Relieve Endoplasmic Reticulum Stress by Autophagy Inhibition in Rats With Permanent Brain Ischemia. Front Neurosci 12:405 (2018). Rozza-de-Menezes RE et al. Prevalence and clinicopathological characteristics of lipomatous neurofibromas in neurofibromatosis 1: An investigation of 229 cutaneous neurofibromas and a systematic review of the literature. J Cutan Pathol 45:743-753 (2018). Barbhuiya MA et al. Identification of spleen tyrosine kinase as a potential therapeutic target for esophageal squamous cell carcinoma using reverse phase protein arrays. Oncotarget 9:18422-18434 (2018). Xu N et al. Stent-Jailing Technique Reduces Aneurysm Recurrence More Than Stent-Jack Technique by Causing Less Mechanical Forces and Angiogenesis and Inhibiting TGF-ß/Smad2,3,4 Signaling Pathway in Intracranial Aneurysm Patients. Front Physiol 9:1862 (2018). Hu YW et al. Long non-coding RNA NEXN-AS1 mitigates atherosclerosis by regulating the actin-binding protein NEXN. J Clin Invest N/A:N/A (2018). Hindle P et al. The Infrapatellar Fat Pad as a Source of Perivascular Stem Cells with Increased Chondrogenic Potential for Regenerative Medicine. Stem Cells Transl Med 6:77-87 (2017). Yang J et al. Case report of ocular Kaposi's sarcoma. BMC Ophthalmol 17:143 (2017). Cai G et al. Effects of cryopreservation on excretory function, cellular adhesion molecules and vessel lumen formation in human umbilical vein endothelial cells. Mol Med Rep 16:547-552 (2017). ICC/IF ; Human . Hulin-Curtis S et al. Targeting Wnt/ß-Catenin Activated Cells with Dominant-Negative N-cadherin to Reduce Neointima Formation. Mol Ther Methods Clin Dev 5:191-199 (2017). Jia Z et al. Comparison of biological characteristics of nucleus pulposus mesenchymal stem cells derived from non-degenerative and degenerative human nucleus pulposus. Exp Ther Med 13:3574-3580 (2017). Patel MD et al. Pediatric and adult dilated cardiomyopathy represent distinct pathological entities. JCI Insight 2:N/A (2017). Troncoso F et al. Gestational diabetes mellitus is associated with increased pro-migratory activation of vascular endothelial growth factor receptor 2 and reduced expression of vascular endothelial growth factor receptor 1. PLoS One 12:e0182509 (2017). Shao B & Liu E Expression of ING4 is negatively correlated with cellular proliferation and microvessel density in human glioma. Oncol Lett 14:3663-3668 (2017). Tu J et al. High expression of angiogenic factor AGGF1 is an independent prognostic factor for hepatocellular carcinoma. Oncotarget 8:111623-111630 (2017). Zhao W et al. Effect of TGF-ß1 on the Migration and Recruitment of Mesenchymal Stem Cells after Vascular Balloon Injury: Involvement of Matrix Metalloproteinase-14. Sci Rep 6:21176 (2016). IHC-P ; Rat . Liang X et al. Exosomes secreted by mesenchymal stem cells promote endothelial cell angiogenesis by transferring miR-125a. J Cell Sci 129:2182-9 (2016). Yang X et al. Causal relationship between obesity-related traits and TLR4-driven responses at the maternal-fetal interface. Diabetologia 59:2459-2466 (2016). Dehkordi MB et al. A Simple, Rapid, and Efficient Method for Isolating Mesenchymal Stem Cells from the Entire Umbilical Cord. Cell Transplant 25:1287-1297 (2016). Sidney LE et al. Phenotypic Change and Induction of Cytokeratin Expression During In Vitro Culture of Corneal Stromal Cells. Invest Ophthalmol Vis Sci 56:7225-35 (2015). El-Gendy R et al. Investigating the Vascularization of Tissue-Engineered Bone Constructs Using Dental Pulp Cells and 45S5 Bioglass® Scaffolds. Tissue Eng Part A 21:2034-43 (2015). IHC-P . Hu L et al. IGF1 Promotes Adipogenesis by a Lineage Bias of Endogenous Adipose Stem/Progenitor Cells. Stem Cells 33:2483-95 (2015). IF ; Human . Lei P et al. Expression profile of Twist, vascular endothelial growth factor and CD34 in patients with different phases of osteosarcoma. Oncol Lett 10:417-421 (2015). IHC-P ; Human . Guo YT et al. Correlational research of Golgi phosphorylation protein 3 expression in colorectal cancer. World J Gastroenterol 21:13473-9 (2015). Castellsagué J et al. Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine. EMBO Mol Med 7:608-27 (2015). IHC-P . Xue G et al. c-Myc-mediated repression of miR-15-16 in hypoxia is induced by increased HIF-2a and promotes tumor angiogenesis and metastasis by upregulating FGF2. Oncogene N/A:N/A (2014). Wu WC et al. Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients. Proc Natl Acad Sci U S A 111:4221-6 (2014). Human . Hylander BL et al. Origin of the vasculature supporting growth of primary patient tumor xenografts. J Transl Med 11:110 (2013). IHC-Fr, IHC-P ; Human . Fruhwürth S et al. High-density lipoprotein endocytosis in endothelial cells. World J Biol Chem 4:131-40 (2013). IHC-FrFl ; Mouse . Luni C et al. Microliter-bioreactor array with buoyancy-driven stirring for human hematopoietic stem cell culture. Biomicrofluidics 4:N/A (2010). Varoga D et al. Differential expression of vascular endothelial growth factor in glucocorticoid-related osteonecrosis of the femoral head. Clin Orthop Relat Res 467:3273-82 (2009). IHC-P ; Human Varoga D et al. Differential expression of vascular endothelial growth factor in glucocorticoid-related osteonecrosis of the femoral head. Clin Orthop Relat Res 467:3273-82 (2009). IHC-P ; Human . Simonavicius N et al. Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma. Mod Pathol 21:308-15 (2008). IHC-P ; Human Simonavicius N et al. Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma. Mod Pathol 21:308-15 (2008). IHC-P ; Human . Bettencourt MC et al. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 160:459-65 (1998) Bettencourt MC et al. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 160:459-65 (1998). Raspadori D et al. Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases. Leuk Res 21:603-7 (1997) Raspadori D et al. Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases. Leuk Res 21:603-7 (1997). Ramani P et al. QBEND/10, a new monoclonal antibody to endothelium: assessment of its diagnostic utility in paraffin sections. Histopathology 17:237-42 (1990) Ramani P et al. QBEND/10, a new monoclonal antibody to endothelium: assessment of its diagnostic utility in paraffin sections. Histopathology 17:237-42 (1990). |
Protocols
Immunofluorescence protocol - Formaldehyde fixation
- Collect cells from T.c.unit and remove media from petri dish using suction.
- Wash with 1x PBS and remove.
- Incubate cells in pre-warm (37°C) Para-Formaldehyde for 12 minutes at room temperature on an orbital shaker.
- Remove PFA and incubate in 0.5% Triton X-IOO in 1x PBS for 5 minutes at room temperature.
- Prepare blocking reagent, this is also the antibody diluent.
- Wash cells 2x with 1x PBS at room temperature, for 4 minutes/wash on an orbital shaker.
- Block with 1 % NCS and 1x PBS for 30 minutes at room temperature.
- Prepare primary antibodies (50?l/coverslip) and moist staining chambers.
- Wash cells 2x with lx PBS at room temperature and air dry briefly.
- Incubate with primary antibody for 1 hr at room temperature in the dark in staining chambers. During this time prepare the secondary antibody.
- Wash cells 5x with 1x PBS (5 beaker changes/5 counts in each beaker)
- Incubate with secondary antibody for 1 hour at room temperature in the dark in staining chambers.
- Wash cells 5x with 1x PBS.
- Mount in Dapi.
Solutions (prepare fresh the same day of staining).
- * 1x Phosphate buffered saline.
- * Blocking reagent: 1% NCS in 1x PBS (use fresh l0x PBS).
- * Fixation solution: 3.5% Para formaldehyde.
1.75g PFA in 20 ml d.H20 plus 5 drops 1M NaOH. Stir on a hot plate at 50-60°C until dissolved. Add 4 drops IN HCI and check pH indicator strip. PH should be 7.4. Complete volume with d.H20 to 25ml and add 25ml 2xPBS. Check pH before adding to cover slips.
Immunofluorescence protocol - Methanol/acetone fixation
- Collect cells from T.C.unit and remove media from petri dish using suction.
- Wash with 1x PBS and remove.
- Fix cells with cold methanol: acetone 1: 1 for 10 minutes on ice.
- Prepare blocking reagent, this is also the diluent for the antibodies.
- Remove fixative and wash cells 3x with Ix PBS at RT, for 4 minutes/wash on orbital shaker.
- Block with 1% NCS and Ix PBS for 30 minutes at RT.
- Prepare primary antibodies (50?l/coverslip) and moist staining chambers.
- Wash cells 2x with 1 x PBS at RT and air dry for approximately 7 minutes.
- Incubate with primary antibody for 1 hr at RT in the dark in staining chambers. During this time prepare secondary antibody.
- Wash cells 5x with 1x PBS (5 beaker changes/5 counts in each beaker)
- Incubate with secondary antibody for 1 hr at R T in the dark in staining chambers.
- Wash cells 5x with 1x PBS.
- Mount in Dapi.
Solutions (prepare fresh the same day of staining)
- * 1x Phosphate buffered saline.
- * Blocking reagent: 1% NCS in 1x PBS (use fresh 10x PBS).
- * Fixation solution: methanol:acetone 1: 1 ice cold.
Western Blotting Protocol
- Transfer gel to PDVF or nitrocellulose membrane
- Place membrane in plastic tray in blocking buffer for one hour with agitation
- Rinse in wash buffer
- Incubate in wash buffer plus primary antibody for one hour
- Wash 6 X 5 minutes with wash buffer
- Incubate in wash buffer plus secondary antibody for one hour
- Wash 6X 5 minutes with wash buffer
- Detect (e.g. ECL, Amersham according to manufacturers instructions)
Wash buffer
PBS + 0.1% Tween 20
Blocking buffer
Wash buffer + 5% dried milk powder
The concentration of antibodies used depends on each antibody, the amount of antigen and the detection method used. Generally, dilution is in the range of a few hundred times dilution to a few thousand times dilution, but usually has to be determined empirically.
FAQ's
How do I place an order?
When placing an order we require a purchase order number, plus name and contact details of the purchaser, and the person who will be using the product. We will add VAT for every order received from an EU country, unless you are VAT exempt. For such VAT exempt customers we will need to receive a copy of the exemption certificate with the order.
Orders can be placed either by our website, via email or by mail. Please see our contact us page for more details
All orders are subject to availability. Prices of products do not include shipping, VAT or import duties, where these are applicable.
Price and other information provided are subject to change without notice. While every effort is made to keep information provided Up to date, ImmuQuest will not be liable if errors should occur in such information.
Formal acceptance of an order will take place when the goods are dispatched. If prices should be changed between the time of receipt of an order and dispatch, ImmuQuest will contact you in advance.
Ordering via the website
To order via the website you will need to find the product(s) you are looking for by either using our search, browsing our categories or using our full antibody catalogue.
Once you have found the antibodies you are looking for you can view more detailed information about a specific antibody by clicking the product or the 'View' button. Once you are sure it is the antibody you are looking for you can add it to your order by clicking the 'Add To Order' button.
This places the antibody in your order basket, you can add as many antibodies as you wish. Once you have selected all of the antibodies you wish to order then click the checkout button. If you are not logged in you will be asked to login or to register, if you are logged in you will be taken to the checkout page.
On the checkout page you are able to double check your order and enter a purchase order number if you have one.
Once you are happy your order is correct you can purchase the order with debit/credit card details and your order will be submitted. Once we have received and checked your order we will contact you to arrange payment and delivery.
How long does delivery take?
Delivery usually takes no more than one week from reciept of an order.
Do you guarantee your antibodies?
Yes. Should any product not perform as described in the product literature, it will be replaced or a full refund will be given. The customer must notify ImmuQuest within 30 days after the goods have been received to request a replacement, forwarding complete test data as requested by ImmuQuest.
If items are ordered incorrectly by the customer, ImmuQuest will consider taking them back as long as they have been stored correctly and have not been opened or tampered with. Such orders may be subject to a 15% restocking charge on the items plus any shipping costs.
Requests for returns must have prior authorization from ImmuQuest, and must be made within 7 days of receipt of the items. Items must be returned in the same or equivalent packaging as originally dispatched, and by an equivalent method of delivery.
Do you charge VAT?
If you are in the EU and you are no exempt from paying VAT then we must charge VAT (charged at the prevailing UK rate).
Customers that are exempt need to fax an exemption form showing their vat exemption number.
What if I don't have a purchase order number?
You can still place an order without providing a purchase order number but we must recieve payment before your order is despatched.
Non-website orders
Non-website orders can be placed directly with Immuquest at sales@immuquest.com or click on the "contact us" tab for address details
Delivery
Offline Orders
For offline orders please call +44 (0) 1642 713533 or click here to email us.
Delivery & returns
We use federal Express for UK & international shipments, andfor standard shipments the cost is £30 UK & £55 international. If the customer uses their account, we charge a £20 handling fee (UK & international)
We are strongly committed to providing the best quality products, and the best service possible.
Should any product not perform as described in the product literature, it will be replaced or a full refund will be given. The customer must notify ImmuQuest within 30 days after the goods have been received to request a replacement, forwarding complete test data as requested by ImmuQuest.
If items are ordered incorrectly by the customer, ImmuQuest will consider taking them back as long as they have been stored correctly and have not been opened or tampered with. Such orders may be subject to a 15% restocking charge on the items plus any shipping costs.
Requests for returns must have prior authorization from ImmuQuest, and must be made within 7 days of receipt of the items. Items must be returned in the same or equivalent packaging as originally dispatched, and by an equivalent method of delivery.
Product Guarantee
We are strongly committed to providing the best quality products, and the best service possible. In order to do this we depend on your feedback.
Should any product not perform as described in the product literature, it will be replaced or a full refund will be given. The customer must notify ImmuQuest within 30 days after the goods have been received to request a replacement, forwarding complete test data as requested by ImmuQuest.
If items are ordered incorrectly by the customer, ImmuQuest will consider taking them back as long as they have been stored correctly and have not been opened or tampered with. Such orders may be subject to a 15% restocking charge on the items plus any shipping costs.
Requests for returns must have prior authorization from ImmuQuest, and must be made within 7 days of receipt of the items. Items must be returned in the same or equivalent packaging as originally dispatched, and by an equivalent method of delivery.
If you have any questions please contact us using the following details:
ImmuQuest Ltd
Springboard
Stokesley Business Park
24 Ellerbeck Way
Stokesley
TS9 5JZ
UK
Tel: 01642 713533
Fax: 01642 713988
International Tel: +44 1642 713533
International Fax: +44 1642 713988
When placing an order ImmuQuest require a purchase order number, plus name and contact details of the purchaser, and the person who will be using the product. ImmuQuest will also need a VAT number for customers in the European Union.UK customers that are VAT exempt need to fax an exemption certificate.
Orders can be placed either by our website, via email or by mail. Please see our contact us page for more details. All orders are subject to availability. Prices of products do not include shipping, VAT or import duties where these are applicable.
Price and other information provided are subject to change without notice. While every effort is made to keep information provided Up to date, ImmuQuest will not be liable if errors should occur in such information. Formal acceptance of an order will take place when the goods are dispatched. If prices should be changed between the time of receipt of an order and dispatch, ImmuQuest will contact you in advance.